University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Nicholas A. Butowski

Nicholas A. Butowski, M.D.

Neuro-oncologist

Dr. Nicholas Butowski is a neuro-oncologist who specializes in brain tumors, neuro-imaging, cognitive and rehabilitative neurology and complementary therapy. He is director of clinical services in Neuro-oncology and a researcher in the Brain Tumor Research Center.

In his research, he focuses on the development of treatments for primary brain tumors as well as methods to ensure good quality of life for patients and methods to assist them in recovering from or coping with brain injury. Butowski earned a medical degree at the University of Illinois in Chicago, and completed a residency in neurology and a fellowship in neuro-oncology at UCSF. He is a member of the American Academy of Neurology, American Society of Clinical Oncology, International Society of Neuro-oncology and Society for Neuro-oncology. He is an associate professor of neurological surgery at UCSF.

Conditions & Treatments

Clinics

Neuro-Oncology Clinic
400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143
Phone: (415) 353-2966
Fax: (415) 353-2167

Hours: Monday to Friday
8 a.m. – 5 p.m.

More about Nicholas A. Butowski

Education

University of Illinois College of Medicine 1999

Residencies

UCSF Medical Center, Neurology 2003

Fellowships

UCSF Medical Center, Neuro-oncology 2004

Selected Research and Publications

  1. Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery. 2012 Feb; 70(2):361-70.
  2. Butowski NA, Chang SM. General and neurological complications of targeted therapy. Handb Clin Neurol. 2012; 105:937-45.
  3. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 1; 29(31):4175-80.
  4. Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011 Dec; 13(12):1331-8.
  5. Butowski N. Anti-angiogenic therapy in glioma. Clin Transl Oncol. 2011 May; 13(5):294-300.
  6. Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Vrionis FD, Wen PY. Central nervous system cancers. J Natl Compr Canc Netw. 2011 Apr; 9(4):352-400.
  7. Parvataneni R, Polley MY, Freeman T, Lamborn K, Prados M, Butowski N, Liu R, Clarke J, Page M, Rabbitt J, Fedoroff A, Clow E, Hsieh E, Kivett V, Deboer R, Chang S. Identifying the needs of brain tumor patients and their caregivers. J Neurooncol. 2011 Sep; 104(3):737-44.
  8. Butowski N. Medical management of brain metastases. Neurosurg Clin N Am. 2011 Jan; 22(1):27-36, v-vi.
  9. Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MY, Sughrue ME, McDermott MW, Parsa AT, Berger MS, Aghi MK. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg. 2011 Jun; 114(6):1609-16.
  10. Essock-Burns E, Lupo JM, Cha S, Polley MY, Butowski NA, Chang SM, Nelson SJ. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011 Jan; 13(1):119-31.
  11. Khayal IS, Polley MY, Jalbert L, Elkhaled A, Chang SM, Cha S, Butowski NA, Nelson SJ. Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. Neuro Oncol. 2010 Sep; 12(9):908-16.
  12. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010 Aug; 12(8):855-61.
  13. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol. 2010 Mar; 67(3):279-83.
  14. Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M, Musib L, Nicol SJ, Thornton DE, Prados MD. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol. 2010 Jun; 12(6):608-13.
  15. Butowski N. Immunostimulants for malignant gliomas. Neurosurg Clin N Am. 2010 Jan; 21(1):53-65.
  16. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010 Mar; 12(3):274-82.
  17. Chang SM, Nelson S, Vandenberg S, Cha S, Prados M, Butowski N, McDermott M, Parsa AT, Aghi M, Clarke J, Berger M. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol. 2009 May; 92(3):401-15.
  18. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009 Feb 1; 27(4):579-84.
  19. Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, Barbaro NM, Parsa AT, Berger MS, McDermott MM. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg. 2008 Nov; 109(5):817-24.
  20. Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol. 2009 Jan; 91(2):183-9.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2012 The Regents of The University of California